FDA Approves New Drug for blood cancer

The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers

(White Plains, NY) - July 23, 2014 - Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. 

For full report follow this link:


go to LLS.org to find out how you can help

No comments

Post a Comment

Blog design by Rainy Day